Futura Medical, GlaxoSmithKline deal

Futura said it mutually agreed with GlaxoSmithKline to terminate a 2010 co-development deal for Futura's pain relief product TPR100. The product, which is in Phase III testing, is a topical gel that comprises the non-steroidal anti-inflammatory drug (NSAID) diclofenac and utilizes Futura's DermaSys drug delivery technology. Under the deal, GSK was responsible for all clinical and regulatory development of TPR100 and was making annual payments to Futura. Futura said that the deal ended for "non-clinical strategic reasons." ...